Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

New Horizon Health Raises $20 Million for China Early-Stage Cancer Tests

publication date: Apr 21, 2020

New Horizon Health of Hangzhou completed a $20 million Series D financing to support its early-stage cancer screening products. Founded in 2013, New Horizon has launched at-home cancer screening products for colorectal cancer, cervical cancer, gastric cancer and lung cancer. The company claims to have served more than three million customers. New Horizon plans to use the funds to develop new products, make a large-scale investment in clinical research and upgrade its service system. The round was led by Omniscience, a private equity fund. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital